Interestingly, Nakamura et al. recently reported that treatment with sodium–glucose cotransporter-2 (SGLT2) inhibitors, which have been shown to significantly attenuate the progression of CKD (Herrington et al., 2023), improved muscle endurance via AMPK activation in a diabetic murine model (Nakamura et al., 2023). Here, SLC5A2 is linked to chronic kidney disease.